Industry Advisory Board
The main tasks of our Industrial Advisory Boards are to advise us on our development strategy, provide us with scientific support, assist us in the drug selection for our pharmaceutical program, advise us on commercialization, partnering and licensing strategies and expand our network for accessing technologies and experts.
Members of our Industrial Advisory Boards meet periodically with our Management Team and our development teams. Our Industrial Advisory Boards have no formal powers under the Articles of Association or Dutch law.
The Industrial Advisory Board for our pharmaceutical development program is currently composed of the following members:
Philip L. Smith - Chairman
Mr. Smith is also a member of our Supervisory Board. He became a member of our Supervisory Board as per December 17, 2003. He was nominated by S.R. One, one of our Major Shareholders. He is also chairman of our Industrial Advisory Board of our pharmaceutical program. Mr. Smith holds a BA in Chemistry from the University of Maine and an MS and PhD in Medicinal Chemistry/Pharmacology from the Northeastern University of Boston. He gained vast experience in the pharmaceutical industry, working for SmithKline Beecham (now GlaxoSmithKline) for 17 years, where he was group director of Drug Delivery Systems for the last two years (until 2002). Mr. Smith has published more than 100 scientific articles. Currently, he is on the board of directors of Redpoint Bio Co. (as of 2003), Onyvax Ltd. (as of 2003), CyDex Inc. (as of 2004), OctoPlus N.V. (as of 2004), and Trinity Biosystems Inc. (as of 2006). Since 2002, he is a general partner of S.R. One.
Chris Lipinski - Member
Mr. Lipinski is an expert in the area drug development and pharmaceutics. He is the inventor of the Rule of Five, a well known method to determine whether a drug candidate has attractive properties to act as an orally active drug, which is used by pharmaceutical scientists around the world. He holds a PhD in physico-organic chemistry from the University of California, Berkeley, US. He was Senior Research Fellow at Pfizer's Global R&D center in Groton, US and has worked at Pfizer in drug discovery, medicinal chemistry, computational chemistry and exploratory medicinal sciences for a period of 32 years. He is recipient of several scientific awards, including an honorary law degree from the University of Dundee, the SBS Achievement Award for Innovation in High-Throughput Screening, and the Division of Medicinal Chemistry Award of the American Chemical Society Division of Medicinal Chemistry. He is the author of 210 scientific publications and is named as inventor of 17 patents.
Brian Morgan - Member
Dr. Morgan is a licensing and business development expert in the pharmaceutical industry. He holds a PhD in Biochemistry from the University of Liverpool. He worked for Beecham and SmithKline Beecham, now GlaxoSmithKline, for nearly 30 years, where he was head of preclinical research from 1982 to 1989 and then, until 1997, vice president Scientific Licensing Worldwide Business Development. Formerly, he was a member of the supervisory boards of Avidis., Beecham Industry, and non-executive director of Oratol., Phairson Medical, D-Pharm. and KS Biomedix. He was also member of the research advisory group of the Diabetes & Metabolic Group of the University of Buckingham and member of the scientific advisory boards of Provalis and Sosei. Currently, he is non-executive director of Scottish Biomedical, 4SC, Protaffin and principal of Morgan Consulting.
John N. Staniforth - Member
Dr. Staniforth is an expert in the area of drug delivery and formulation development. He is an Honorary professor of the University of Bath, England. He is also non-executive director for Penwest Pharmaceuticals., scientific advisor for Vectura and chief scientific officer for Pharmakodex (a spin out of Vectura and Unilever). Dr. Staniforth has vast experience in pharmaceutical technology and has received numerous awards, including the Churchill Fellowship and most recently, the AstraZeneca Award for Industrial Achievement. He is the author of over 100 scientific publications and is named as inventor or co-inventor of several drug delivery technologies including technologies that have been commercialized.
Ronald van der Geest - Member
Mr. Van der Geest has vast experience in clinical pharmacokinetics and the development of novel drugs, predominantly for HIV. He holds a PhD in Pharmacokinetics from the University of Leiden, the Netherlands. He was global project leader for Tibotec from 2000 to 2004, where he was responsible for Tibotec's HIV protease inhibitor development program. In 2004, Mr. Van der Geest became senior drug development consultant and director clinical pharmacokinetics for Kinesis, where he is now chief operational officer. In addition, he is general manager and co-founder of InPEC, a clinical contract research organization. Mr. Van der Geest is author of 20 scientific articles.
Patrick Camilleri - Member
Mr. Camilleri has vast experience in drug research, in particular the determination of physico-chemical properties of drug molecules. He holds a PhD in Physical Chemistry from the University of Wales. He started his industrial career at Shell in 1979 where he headed the physical-organic chemistry research group for almost 10 years, before moving to SmithKline Beecham, where he was director of analytical sciences and director bioanalytical and toxicoproteomics. In 2003 he started his own consultancy firm, Biochemical Solutions. In recognition of his scientific achievements, he was awarded the Analytical Chemistry Gold Medal by the Royal Society of Chemistry. Mr. Camilleri is the author of 195 scientific publications and is named as inventor of 14 patents.
Marcel Hoffmann - Member
Mr. Hoffman is director of our pharmaceutical development program. He holds a PhD in Biochemistry and Molecular Biology from the VU University Amsterdam. In 2001, he joined Galapagos as senior scientist, group leader for their drug discovery programs and head of pharmacology. He joined us in 2006 in his current position. Mr. Hoffman is the author of 14 scientific publications and is named as inventor of four patents.